Skip to main content

Advertisement

Log in

Impact of ‘Chief-Pharmacist System’ on drug expenditures and rational drug use

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Over the last few years, pharmacists in China have been searching for effective strategies to expand their roles in pharmaceutical care. In September 2012, the Beijing Chaoyang Hospital was the first in China to establish the Chief-Pharmacist System aimed to let pharmacists be a responsible part of the multi-disciplinary care team. Objective To describe the Chief-Pharmacist System and explore its impact on drug expenditures and rational drug use. Setting A tertiary hospital in Beijing, China. Method Chief-Pharmacist System oriented specific measures were implemented and evaluated. Data on medical services quantity, quality and drug expenses during the periods of pre-implementation (from September 1, 2011 to August 31, 2012) and post implementation (from September 1, 2012 to August 31, 2016) were collected. Main outcome measure Healthcare quality indicators, drug expenditures, selected drug use indicators of outpatient and antibiotic use. Results With the implementation of the Chief-Pharmacist System and the participation of pharmacists in pharmaceutical care, drug expenses were reduced significantly. The total drug expenses, outpatient drug expenses per visit and inpatient drug expenses per admission decreased by an average of US $34.3 million, US $8.9 and US $ 303.9, respectively, compared to the pre-implementation period. Meanwhile, selected drug use indicators in post-implementation period were significantly improved. All results were achieved without sacrificing clinical quality and quantity. Conclusion The study illustrates that the Chief-Pharmacist System achieves substantial reductions in drug expenditures and promotion of rational drug use. It provides a model for other hospitals in China and other low- and middle-income countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. He Y, Dou G, Huang Q, Zhang X, Ye Y, Qian M, et al. Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study. PLoS ONE. 2018;13:e0190320.

    Article  CAS  Google Scholar 

  2. Promoting rational use of medicines: core components. World Health Organization; 2002. http://apps.who.int/medicinedocs/pdf/h3011e/h3011e.pdf. Accessed 08 Aug 2018.

  3. Fu H, Li L, Li M, Yang C, Hsiao W. An evaluation of systemic reforms of public hospitals: the Sanming model in China. Health Policy Plan. 2017;32:1135–45.

    Article  Google Scholar 

  4. Doucette WR, Nevins JC, Gaither C, Kreling DH, Mott DA, Pedersen CA, et al. Organizational factors influencing pharmacy practice change. Res Social Adm Pharm. 2012;8:274–84.

    Article  Google Scholar 

  5. Tian W, Yuan J, Yang D, Zhang L. Descriptive analysis on the impacts of universal zero-markup drug policy on a chinese urban tertiary hospital. PLoS ONE. 2016;11:e0162795.

    Article  CAS  Google Scholar 

  6. Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. Br J Clin Pharmacol. 2009;68:588–98.

    Article  Google Scholar 

  7. Bond CA, Raehl CL, Patry R. Evidence-based core clinical pharmacy services in United States hospitals in 2020: services and staffing. Pharmacotherapy. 2004;24:427–40.

    Article  CAS  Google Scholar 

  8. Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract. 2017;6:37–46.

    Article  Google Scholar 

  9. Siaw MYL, Ko Y, Malone DC, Tsou KYK, Lew YJ, Foo D, et al. Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial. J Clin Pharm Ther. 2017;42:475–82.

    Article  CAS  Google Scholar 

  10. Houle SK, Chuck AW, McAlister FA, Tsuyuki RT. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Pharmacotherapy. 2012;32:527–37.

    Article  Google Scholar 

  11. Zhou Y, Ma LY, Zhao X, Tian SH, Sun LY, Cui YM. Impact of pharmacist intervention on antibiotic use and prophylactic antibiotic use in urology clean operations. J Clin Pharm Ther. 2015;40:404–8.

    Article  CAS  Google Scholar 

  12. Caffiero N, Delate T, Ehizuelen MD, Vogel K. Effectiveness of a clinical pharmacist medication therapy management program in discontinuation of drugs to avoid in the elderly. J Manag Care Spec Pharm. 2017;23:525–31.

    PubMed  Google Scholar 

  13. Katoue MG, Ker J. Implementing the medicines reconciliation tool in practice: challenges and opportunities for pharmacists in Kuwait. Health Policy. 2018;122:404–11.

    Article  Google Scholar 

  14. Doloresco F, Vermeulen LC. Global survey of hospital pharmacy practice. Am J Health Syst Pharm. 2009;66:S13–9.

    Article  Google Scholar 

  15. Anderson S. The state of the world’s pharmacy: a portrait of the pharmacy profession. J Interprof Care. 2002;16:391–404.

    Article  Google Scholar 

  16. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.

    PubMed  CAS  Google Scholar 

  17. How to investigate drug use in health facilities: selected drug use indicators. World Health Organization; 1993. http://apps.who.int/medicinedocs/pdf/s2289e/s2289e.pdf. Accessed 08 Aug 2018.

  18. ATC/DDD Index 2019. WHO Collaborating Centre for Drug Statistics Methodology. 2019. https://www.whocc.no/atc_ddd_index/. Accessed 01 Aug 2019.

  19. Dong L, Yan H, Wang D. Drug prescribing indicators in village health clinics across 10 provinces of Western China. Fam Pract. 2011;28:63–7.

    Article  Google Scholar 

  20. Li Y, Xu J, Wang F, Wang B, Liu L, Hou W, et al. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Heaalth Aff (Millwood). 2012;31:1075–82.

    Article  Google Scholar 

  21. Zhang HH, Du Y, Liu W, Song SD, Zhao W, Huang GW, et al. Effectiveness of antibiotic use management in Tianjin (2011–2013): a quasi-experimental study. Med Sci Monit. 2017;23:725–31.

    Article  Google Scholar 

  22. Clinical Pharmacy Branch of Chinese Medical Association. Expert consensus on chief pharmacist system of China (2018). Chin J Hosp Adm. 2018;34:793–6.

    Google Scholar 

  23. Yang Z, Fan D. How to solve the crisis behind Bribegate for Chinese doctors. The Lancet. 2012;379:e13–5.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank all pharmacists engaged in this pharmaceutical reform. We appreciate the supports from directors, doctors and nurses of our hospital.

Funding

The Project was supported by the Former National Health and Family Planning Commission Drug Policy and Basic Drug Department, No〔2016〕43

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to LiHong Liu.

Ethics declarations

Conflicts of interest

Authors declare that they have no conflicts of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, Z., Zhao, Z., Sun, S. et al. Impact of ‘Chief-Pharmacist System’ on drug expenditures and rational drug use. Int J Clin Pharm 42, 167–173 (2020). https://doi.org/10.1007/s11096-019-00954-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-019-00954-9

Keywords

Navigation